Novavax Inc NVAX shares are trading higher Tuesday after the company announced the World Health Organization (WHO) issued an updated Emergency Use Listing for its Nuvaxovid vaccine as a primary series in adolescents and as a booster in adults.
The updated listing was based on data from an ongoing pediatric expansion of the Phase 3 PREVENT-19 trial. In the pediatric expansion, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall.
The primary series for adolescents aged 12 through 17 will be delivered as a series of two Nuvaxovid doses.
The updated listing for Nuvaxovid as a booster in adults aged 18 and older is supported by data from Novavax' two Phase 2 trials and a COV-BOOST trial. In the COV-BOOST trial, Nuvaxovid induced a meaningful antibody response when used as a heterologous third booster dose.
The WHO previously granted Emergency Use Listing for Nuvaxovid in adults aged 18 and older in December 2021.
See Also: Nasdaq, S&P Futures Jump As China Signals COVID-19 Policy Relief
NVAX Price Action: Novavax has a 52-week high of $236.50 and a 52-week low of $16.
The stock was up 3% at $17.15 at time of publication, according to Benzinga Pro.
Photo: Jernej Furman from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
